In Vivo Polychromatic Erythrocyte Micronucleus Test for Medical Devices (ISO 10993-3 / OECD 474)

The in vivo polychromatic erythrocyte (PCE) micronucleus test is a core genotoxicity assay used to evaluate whether extracts from medical devices can induce chromosome damage in rodent bone marrow. Conducted in accordance with ISO 10993-3 (adopted in China as GB/T 16886.3) and OECD Test Guideline 474, this study is a regulatory expectation for devices with prolonged or long-term patient contact, blood contact, or implantable applications. This article explains the scientific principle, sample preparation, methodology, acceptance criteria, and practical applications of the medical device PCE micronucleus test.

Technical Overview

The polychromatic erythrocyte (PCE) micronucleus test is an in vivo genotoxicity assay that detects structural and numerical chromosome damage in mammalian hematopoietic cells. Micronuclei are small, membrane-bound cytoplasmic bodies containing DNA. They originate either from acentric chromosome fragments generated by chromosome breakage (a clastogenic mechanism) or from whole chromosomes that lag behind during anaphase and fail to be incorporated into the main daughter nuclei (an aneugenic mechanism). When erythroblasts in the bone marrow complete their final division and expel the main nucleus during maturation, any micronucleus that has formed is retained in the cytoplasm of the immature, polychromatic erythrocyte.

Because mature PCEs lack a main nucleus, any DNA-containing body visible in the cytoplasm can be attributed directly to chromosome damage that occurred during the preceding mitosis. This makes PCEs an exceptionally clean and sensitive target cell population for detecting genotoxic insult. PCEs can be readily distinguished from mature normochromatic erythrocytes (NCEs) by selective staining, and the proportion of immature erythrocytes among total erythrocytes serves as a concurrent marker of bone marrow toxicity and target-tissue exposure.

For medical devices, the test is performed on device extracts rather than on the device itself, because most devices are solid materials whose leachable substances are the potential genotoxic agents. The study is conducted within the biological evaluation framework of ISO 10993-1 and the test selection logic of ISO 10993-3, using sample preparation procedures defined in ISO 10993-12. The conduct of the assay itself follows OECD Test Guideline 474 (Mammalian Erythrocyte Micronucleus Test, adopted 2016). In the Chinese national framework, the corresponding standard is GB/T 16886.3. Key reference documents include:

• ISO 10993-1: Biological evaluation of medical devices — Part 1: Evaluation and testing within a risk management process
• ISO 10993-3: Tests for genotoxicity, carcinogenicity and reproductive toxicity
• ISO 10993-12: Sample preparation and reference materials
• OECD Test Guideline 474: Mammalian Erythrocyte Micronucleus Test
• OECD Principles of Good Laboratory Practice (GLP)

Testing Samples

Device Categories Requiring Evaluation

Genotoxicity testing, including the in vivo micronucleus assay, is typically triggered by the device categorization described in ISO 10993-1. Devices commonly evaluated include:

• Surface medical devices with mucosal membrane contact or contact with breached or compromised surface for prolonged durations (e.g., wound dressings, catheter-fixation dressings)
• External communicating devices with indirect blood-path, circulatory system, or tissue, bone, or dentin contact (e.g., intravenous catheters, infusion sets, hemodialysis tubing, dialyzers)
• Implantable devices with tissue or bone contact (e.g., orthopedic implants, cardiac stents, pacemaker leads, absorbable sutures and scaffolds, dental implants)
• Devices manufactured from new or modified polymers, elastomers, ceramics, composites, coatings, or resorbable materials
• Devices for which in vitro genotoxicity assays (bacterial reverse mutation or chromosomal aberration tests) have produced equivocal or positive findings that require in vivo follow-up

Test Sample and Extract Preparation

Because the genotoxic hazard of a device resides in its leachable substances, test articles are prepared as extracts in both a polar and a non-polar solvent to cover the range of possible extractable chemistries. Typical extraction vehicles include 0.9% sodium chloride injection or cell culture medium (polar) and sesame seed oil, corn oil, or similar pharmacopoeial oils (non-polar). Extraction is performed under aseptic conditions using standardized surface-area-to-volume ratios defined in ISO 10993-12, for example 6 cm² per mL for polymer thicknesses below 0.5 mm and 3 cm² per mL for thicknesses of 0.5 to 1 mm; mass-based ratios (commonly 0.1 to 0.2 g per mL) are applied to irregularly shaped or porous devices.

Extraction conditions are chosen to exaggerate, without degrading, the release of leachables while remaining clinically relevant. Standard condition sets include 37 °C for 24 ± 2 hours, 37 °C for 72 hours, 50 °C for 72 hours, 70 °C for 24 hours, or 121 °C for 1 hour. Extracts are used promptly after preparation to avoid instability or secondary chemical changes, and an identical blank vehicle processed under the same extraction conditions serves as the negative control.

Testing Items

The core measurements and observations generated by the study include:

• Frequency of micronucleated polychromatic erythrocytes (MnPCE) in bone marrow, based on blinded scoring of at least 2,000 PCEs per animal
• Proportion of immature (polychromatic) erythrocytes among total erythrocytes, scored over at least 200 erythrocytes per animal, as an index of bone marrow cytotoxicity and systemic exposure
• Clinical observations, mortality checks, and body-weight records throughout the observation period
• Bone marrow cellularity and slide quality assessments as part of assay validity
• Comparison of all treated groups against the concurrent negative (vehicle) control and the positive control group

Testing Methods

Test System and Experimental Design

Healthy young adult rodents, most commonly mice (for example ICR, NIH, or BALB/c strains) or rats (Sprague-Dawley or Wistar), are used. Each treatment group typically comprises five animals per sex, or a single sex with scientific justification. A standard design includes a negative control group (blank extraction vehicle), one or more groups receiving the test extract at the maximum feasible concentration, additional dilution levels where warranted, and a positive control group treated with a known clastogen such as cyclophosphamide or mitomycin C. Animals are acclimatized before the study and randomized to groups to minimize bias.

Dose Administration

Device extracts are generally administered by intravenous or intraperitoneal injection, which maximizes systemic availability of any leachable genotoxins; alternative routes require scientific justification. Because device extracts are not classic chemicals, dosing is based on the maximum tolerated and technically feasible volume, with administration volumes in mice typically not exceeding approximately 5 mL/kg intravenously or 10 mL/kg intraperitoneally, consistent with good animal welfare practice. A single-exposure design with bone marrow sampling at approximately 24 hours (high dose) and 48 hours is standard under OECD TG 474; repeated daily administration over two to three consecutive days with a single post-dose harvest is also an accepted approach for device extracts when scientifically justified.

Bone Marrow Sampling and Slide Preparation

At the scheduled harvest times, animals are humanely euthanized and bone marrow is collected from the femur or tibia. Marrow cells are flushed, concentrated, spread onto clean microscope slides, fixed, and stained. Giemsa staining permits light-microscopic differentiation of PCEs (bluish-purple cytoplasm) from NCEs (pink to orange cytoplasm), while fluorescence staining with acridine orange provides higher contrast and faster scoring. All slides are coded prior to analysis so that scoring is performed blind to treatment group, and micronucleus identification follows defined criteria: the micronucleus must be round, morphologically comparable to the main nucleus in staining intensity, generally between 1/20 and 1/5 the diameter of the erythrocyte, clearly separated from the main cell body, and located within the cytoplasmic boundary.

Data Analysis and Interpretation Criteria

Group frequencies of MnPCE are analyzed with appropriate statistical methods, such as the Kastenbaum-Bowman test, Fisher exact test, or a Cochran-Armitage trend test. A result is considered positive when the test extract produces a statistically significant, dose- or exposure-related increase in MnPCE frequency that exceeds the laboratory's historical negative control distribution and is reproducible across sampling times. A result is negative when no such increase occurs and the assay validity criteria are met, demonstrating that the bone marrow was exposed (adequate proportion of immature erythrocytes) without confounding toxicity.

Assay Validity and Quality Requirements

The assay is accepted only when the following conditions are satisfied:

• Negative control MnPCE frequencies fall within the laboratory's historical control range
• The positive control induces a statistically significant and biologically meaningful increase in MnPCE frequency, confirming assay sensitivity
• Scoring targets (at least 2,000 PCEs per animal for micronucleus frequency; at least 200 total erythrocytes per animal for the immaturity index) are achieved
• No excessive systemic toxicity or mortality confounds interpretation
• The study is conducted under GLP with protocol, raw data, and archival integrity

Animal welfare is safeguarded through institutional ethical review, adherence to the 3Rs principles (replacement, reduction, refinement), and humane endpoints throughout the study.

Applications

The in vivo PCE micronucleus test is a pivotal component of the biological safety dossier for medical devices across major regulatory jurisdictions, including China, the United States, the European Union, and Japan. Its principal applications include:

• Genotoxicity hazard identification required by ISO 10993-3 for devices with prolonged (24 hours to 30 days) or long-term (more than 30 days) contact, and for blood-contacting or implantable devices
• Follow-up testing to clarify positive or equivocal results from in vitro assays such as the bacterial reverse mutation test or the chromosomal aberration test
• Support for regulatory submissions, including registration dossiers and technical files reviewed under national medical device regulations and notified body conformity assessment
• Evaluation of material, formulation, coating, sterilization, or manufacturing process changes during product development and change control
• Input to toxicological risk assessment within the ISO 10993-1 and ISO 14971 risk management framework, often combined with chemical characterization per ISO 10993-18
• Resolving genotoxicity questions for biodegradable and drug-device combination products whose degradation products or leachables may reach systemic circulation

Manufacturers frequently engage accredited third-party laboratories with GLP compliance and validated historical control databases to perform this study, ensuring that the resulting data are acceptable to regulatory reviewers worldwide.

FAQ

When is the in vivo micronucleus test required for a medical device?

Under ISO 10993-3, genotoxicity evaluation is generally expected when a device has contact duration exceeding 24 hours, contacts blood or the circulatory system, is implantable, is resorbable, or when chemistry or in vitro data suggest genotoxic potential. The in vivo micronucleus test is commonly performed as part of the standard genotoxicity battery or as a confirmatory follow-up to in vitro findings.

Why are polychromatic erythrocytes used instead of normochromatic erythrocytes?

PCEs are immature erythrocytes that have just expelled their main nucleus but retain any micronucleus formed during the preceding cell division. Because they have no main nucleus to obscure or be confused with DNA fragments, PCEs provide a direct and sensitive readout of recent chromosome damage. NCEs, by contrast, have circulated longer, and their micronucleus content reflects older, dilution-blurred exposures.

Why must both polar and non-polar extracts be tested?

Device leachables span a wide range of polarity, from hydrophilic residues such as monomers and salts to hydrophobic additives, plasticizers, and oligomers. Extracting in both a polar solvent and a non-polar solvent ensures that the genotoxicity screen does not miss a chemically relevant leachable simply because it partitions into only one type of vehicle.

What positive and negative controls are used?

The negative control is the blank extraction vehicle processed under identical extraction conditions without the device. The positive control is a validated clastogen or aneugen, most commonly cyclophosphamide for clastogenicity, administered at a dose and harvest time known from historical data to produce a clear increase in micronucleus frequency.

What happens if the test result is positive?

A positive finding does not automatically disqualify the device. Sponsors typically conduct a weight-of-evidence review that includes repeating or extending the assay, performing complementary tests such as the rodent Comet assay (OECD TG 489), chemical characterization of leachables, and a toxicological risk assessment to determine whether patient exposure levels present an acceptable benefit-risk balance.

How long does the study take?

From extraction and animal acclimation through dosing, harvest, blinded slide scoring, statistical analysis, and GLP report finalization, a typical study is completed within approximately six to twelve weeks, depending on the number of extract types, dose levels, and any repeat analyses.

Can peripheral blood be used instead of bone marrow?

Yes. OECD TG 474 permits micronucleus analysis in peripheral blood immature erythrocytes for mouse studies, including repeated-dose integration. However, bone marrow remains the standard tissue for device extract evaluations because it is the site of active erythropoiesis and gives the most responsive measurement of recent genotoxic injury.